RTx-021

· Ray Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RTx-021, covering 2026-04-15 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease [Phase 1, Phase 2]

See pricing